Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study

References

• Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632–638.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica G W, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
   PubMed Web of Science ®Google Scholar
• Fritscher L, Chapman KR. Omalizumab for asthma: Pharmacology and clinical profile. Expert Rev Resp Med 2009; 3(2):119–127.
   PubMedGoogle Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302–308.
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium. Omalizumab 150mg powder and solvent for injection (Xolair®) (No. 259/06). 2007. Available at: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/Omalizumab__Xolair_/omalizumab_150mg_powder_and_solvent_for_injection__Xolair_1.Accessed April 24, 2013.
   Google Scholar
• Scottish Medicines Consortium. Omalizumab 150 mg powder and solvent for solution for injection (Xolair®) (No: 611/10). 2010 Product Update. Available at: http://www.scottishmedicines.org.uk/files/OmalizumabXolair_Abbreviated_Mar2010.pdf. Accessed April 24, 2013.
   Google Scholar
• National Institute for Health and Clinical Excellence. Omalizumab for severe persistent allergic asthma. NICE technology appraisal TA133. Available at: http://guidance.nice.org.uk/TA133. Accessed May 11, 2012.
   Google Scholar
• Lewis LD, Cochrane GM. Systemic steroids in chronic severe asthma. Br Med J (Clin Res Ed) 1986; 292:1289–1290.
   PubMed Web of Science ®Google Scholar
• Yuen P Office of Health Economics. Compendium of Health Statistics 2003–2004, Office of Health Economics, London 2003.
   Google Scholar
• Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I.“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103:1633–1642.
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France. Respir Med 2008; 102:71–76.
   PubMed Web of Science ®Google Scholar
• Zureik M, Molimard M, Aubier M, Levy J, Humbert M, Grimaldi-Bensouda L, Abenhaim L; Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group. Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort. European Respiratory Society (ERS) Congress 18–22 September 2010, Barcelona, Spain.
   Google Scholar
• Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103:1725–1731.
   PubMed Web of Science ®Google Scholar
• Vennera MDC, De Llano LP, Bardagi S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Álvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C, on behalf of the Spanish Registry. Omalizumab therapy in severe asthma: Experience from the Spanish Registry—Some new approaches. J Asthma 2012; 49:416–422.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M. Longitudinal changes in asthma control with Omalizumab: 2 year interim data from the EXCELS study. J Asthma 2012; 49:642–648.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pradelli LA. 36 month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic7asthma in Italy. J Asthma 2012; 49:843–848.
   PubMed Web of Science ®Google Scholar
• Niven R, McBryan D. A UK survey of oral corticosteroid use in patients treated with omalizumab. Thorax 2007; 62(suppl. 3):A98 ( Abstract P91).
   Google Scholar
• Simons S, Regan K, Aziz A, Saralaya D. Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital. Am J Respir Crit Care Med 2010; 181:A1336.
   PubMed Web of Science ®Google Scholar
• Knowles V, Nordstrom M, Britton M. Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital. Eur Respir J 2009;34(suppl. 53): 315s, E1875 (Abstract).
   Google Scholar
• Gibeon D, Campbell DA, Regan SE, Menzies-Gow A. The effectiveness of omalizumab in severe allergic asthma is comparable in patients selected by NICE or SMC criteria. Am J Respir Crit Care Med 2009; 179:A2812 (Abstract).
   Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59–65.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax 1992; 47:76–83.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary. 64th ed. London: BMJ Group and Pharmaceutical Press, 2012.
   Google Scholar
• European Medicines Agency. Xolair 150 mg powder and solvent for solution for injection summary of product characteristics [online]. Available at: http://www.medicines.org.uk/emc/medicine/17029#POSOLOGY. Accessed May 11, 2012.
   Google Scholar
• Walsh L, Wong C, Oborne J, Cooper S, Lewis SA, Pringle M, Hubbard R, Tattersfield AE. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56: 279–284.
   PubMed Web of Science ®Google Scholar
• Covar RA, Leung DYM, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. The Journal of Allergy and Clinical Immunology 2000; 106: 651–9.
   PubMed Web of Science ®Google Scholar
• Molimard M, Chanez P, Pison C, Tétu L, Le Gros V. Long term follow-up of patients under omalizumab initiated during the pre-approval period in France. European Respiratory Society Annual Congress 2010 (Abstract #250607)
   Google Scholar
• Costello RW, Long DAA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180:637–641.
   PubMed Web of Science ®Google Scholar
• Schatz M, Camargo CA Jr. The relationship of sex to asthma prevalence, health care utilization and medications in a large managed care organization. Ann Allergy Asthma Immunol 2003; 91:553–558.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Camiciottoli G, Bonavia M, . Italian real-life experience of omalizumab. Respir Med 2010; 104:1410–1416.
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Leo J, Chen CW, Maykut R, Georgiou P, Peachey G. The eXpeRience registry: Monitoring the ‘real-world’ effectiveness of omalizumab in allergic asthma. Poster presentation (P3953) at the European Respiratory Society Annual Congress 2011, Amsterdam, NL.
   Google Scholar